In theory, Motif Neurotech's berry-sized device would work like a continuous glucose monitor. More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Patients receiving the experimental new implant would not need to undergo a complicated surgery. Breakthroughs, discoveries, and DIY tips sent six days a week. Earlier this week, the United States Food and Drug Administration (FDA) approved a human trial for a blueberry-sized brain implant intended to target treatment-resistant depression.

Placebo and "knowcebo" effects are a problem. But they can also help people feel better. This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin--which is found in magic mushrooms--are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over the last decade, we've seen scientific interest in these drugs explode. But most clinical trials of psychedelics have been small and plagued by challenges.

Prolonged grief disorder affects around 1 in 20 people, and we're starting to understand the neuroscience behind it For most people, the intense sting of grief eases with time. For some, however, persistent and painful grief remains, developing into prolonged grief disorder. A new review of the condition, which affects around 5 per cent of bereaved people, sheds light on how it develops. This could help doctors predict which recently bereaved people will benefit from extra support. The decision to include prolonged grief disorder (PGD) in the American Psychiatric Association's diagnostic manual in 2022 sparked intense debate over whether it was pathologising a normal human response to loss and imposing an arbitrary timeline on what constitutes "normal" grief.

For years, people from CEOs to novelists have taken tiny amounts of psychedelics to support well-being. New research shows that benefits for depression may be attributable to a placebo effect. Typically using psilocybin mushrooms or LSD, the archetypal microdoser sought less melting walls and open-eye kaleidoscopic visuals than boosts in mood and energy, like a gentle spring breeze blowing through the mind. Anecdotal reports pitched microdosing as a kind of psychedelic Swiss Army knife, providing everything from increased focus to a spiked libido and (perhaps most promisingly) lowered reported levels of depression. It was a miracle for many.

Flow Neuroscience receives FDA approval for FL-100 depression device showing 58% symptom improvement. The home-use brain stimulation headset will be available in 2026.

As rates of mental health conditions like depression spike, we desperately need new ways of identifying and treating people in distress. The last big breakthrough in treating depression was all the way back in the 1980s. That was when Prozac, the first SSRI antidepressant, was released. It and its subsequent copycats soon swept the globe, and hundreds of millions of people have now taken this kind of medication. But while three-quarters of people say the pills have helped them feel better, they don't work for everyone.

"It seems like this past week has been quite challenging for you," a disembodied voice tells me, before proceeding to ask a series of increasingly personal questions. "Have you been feeling down or depressed?" "Can you describe what this feeling has been like for you?" "Does the feeling lift at all when something good happens?" When I respond to each one, my chatbot interviewer thanks me for my honesty and empathises with any issues. By the end of the conversation, I will have also spoken about my sleep patterns, sex drive and appetite for food.

This study presents QuanvNeXt, an end-to-end fully quanvolutional model for EEG-based depression diagnosis. QuanvNeXt incorporates a novel Cross Residual block, which reduces feature homogeneity and strengthens cross-feature relationships while retaining parameter efficiency. We evaluated QuanvNeXt on two open-source datasets, where it achieved an average accuracy of 93.1% and an average AUC-ROC of 97.2%, outperforming state-of-the-art baselines such as InceptionTime (91.7% accuracy, 95.9% AUC-ROC). An uncertainty analysis across Gaussian noise levels demonstrated well-calibrated predictions, with ECE scores remaining low (0.0436, Dataset 1) to moderate (0.1159, Dataset 2) even at the highest perturbation (ε = 0.1). Additionally, a post-hoc explainable AI analysis confirmed that QuanvNeXt effectively identifies and learns spectrotemporal patterns that distinguish between healthy controls and major depressive disorder. Overall, QuanvNeXt establishes an efficient and reliable approach for EEG-based depression diagnosis.

Healthcare AI systems have historically faced challenges in merging contextual reasoning, long-term state management, and human-verifiable workflows into a cohesive framework. This paper introduces a completely innovative architecture and concept: combining the Model Context Protocol (MCP) with a specific clinical application, known as MCP-AI. This integration allows intelligent agents to reason over extended periods, collaborate securely, and adhere to authentic clinical logic, representing a significant shift away from traditional Clinical Decision Support Systems (CDSS) and prompt-based Large Language Models (LLMs). As healthcare systems become more complex, the need for autonomous, context-aware clinical reasoning frameworks has become urgent. We present MCP-AI, a novel architecture for explainable medical decision-making built upon the Model Context Protocol (MCP) a modular, executable specification for orchestrating generative and descriptive AI agents in real-time workflows. Each MCP file captures clinical objectives, patient context, reasoning state, and task logic, forming a reusable and auditable memory object. Unlike conventional CDSS or stateless prompt-based AI systems, MCP-AI supports adaptive, longitudinal, and collaborative reasoning across care settings. MCP-AI is validated through two use cases: (1) diagnostic modeling of Fragile X Syndrome with comorbid depression, and (2) remote coordination for Type 2 Diabetes and hypertension. In either scenario, the protocol facilitates physician-in-the-loop validation, streamlines clinical processes, and guarantees secure transitions of AI responsibilities between healthcare providers. The system connects with HL7/FHIR interfaces and adheres to regulatory standards, such as HIPAA and FDA SaMD guidelines. MCP-AI provides a scalable basis for interpretable, composable, and safety-oriented AI within upcoming clinical environments.